Keytruda

FDA expands Keytruda approval for first-line NSCLC treatment
FDA expands Keytruda approval for first-line NSCLC treatment
Pharmaforum
Merck
Keytruda
FDA
non-small cell lung cancer
Flag link:
AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups
AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups
Fierce Pharma
Merck
Keytruda
AACR
Flag link:
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Fierce Pharma
Merck
Keytruda
China
advanced non-squamous non-small cell lung cancer
Flag link:
Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?
Will GSK/Tesaro’s Checkpoint Inhibitor Be Able to Compete With Merck’s Keytruda?
BioSpace
GSK
Tesaro
Merck
Keytruda
endometrial cancer
dostarlimab
Flag link:
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Fierce Pharma
Merck
Keytruda
immuno-oncology
China
Flag link:
Merck notches fourth lung cancer approval in Europe for flagship Keytruda
Merck notches fourth lung cancer approval in Europe for flagship Keytruda
Endpoints
Merck
Keytruda
metastatic squamous non-small cell lung cancer
Europe
Flag link:
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
Yahoo/Zacks.com
EMA
CHMP
Keytruda
Merck
Flag link:
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Yahoo/Zacks.com
Merck
Keytruda
advanced SCLC
Flag link:
Merck expands Mass. reach with Torque cancer collaboration
Merck expands Mass. reach with Torque cancer collaboration
Bizjournals
Torque
Merck
Keytruda
immuno-oncology
TRQ-1501
Flag link:
Keytruda gets okay from FDA for adjuvant melanoma
Keytruda gets okay from FDA for adjuvant melanoma
Pharmaforum
FDA
Merck
adjuvant melanoma
melanoma
Keytruda
Flag link:
Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
Endpoints
Merck
Keytruda
clinical trials
liver cancer
Flag link:
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Motley Fool
Pfizer
Inlyta
kidney cancer
Merck
Keytruda
Flag link:
Merck, Pfizer drug combo extends kidney cancer survival -study
Merck, Pfizer drug combo extends kidney cancer survival -study
Yahoo/Reuters
Merck
Pfizer
kidney cancer
Keytruda
Inlyta
Sutent
Flag link:
Keytruda-Inlyta combo under Priority Review for first-line RCC
Keytruda-Inlyta combo under Priority Review for first-line RCC
BioCentury
Merck
Keytruda
Inlyta
renal cell carcinoma
FDA
priority review
Flag link:
Merck plans trio of Phase 3 Keytruda studies in prostate cancer
Merck plans trio of Phase 3 Keytruda studies in prostate cancer
BioPharma Dive
Merck
Keytruda
prostate cancer
clinical trials
Flag link:
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Flag link:
FDA promises speedy review on moving Merck's Keytruda up as first-line head and neck cancer therapy
FDA promises speedy review on moving Merck's Keytruda up as first-line head and neck cancer therapy
Endpoints
Merck
Keytruda
FDA
head and neck cancer
priority review
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
Mark Your Calendar For These February PDUFA Dates
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Flag link:

Pages